April 7, 2022 / 5:30-7:30pm PT

Join us at ASBrS 2022 for a symposium

Personalizing Care for Early Breast Cancer Patients: TAILORx, RxPONDER, and Beyond

Dr. Christy Russell (Vice President, US Medical Affairs at Exact Sciences) will lead a discussion with exploring how the Oncotype DX Breast Recurrence Score® test can help inform systemic therapy decisions for early node-negative and node-positive breast cancer patients. She will also explore ongoing studies on gene signatures that may help personalize radiotherapy decisions in early breast cancer.

Speakers:

Christy Russell, MD
Vice President, US Medical Affairs at Exact Sciences

Corey Speers, MD, PhD
Associate Professor of Radiation Oncology, University of Michigan Medical School

Jennifer Racz, MD, MBA
Associate Professor, Division of Surgical Oncology, University of Wisconsin School of Medicine and Public Health

Speakers

Lead
I agree to be contacted by a representative of Exact Sciences about the Oncotype DX test and accept the Terms & Conditions. For more information about our privacy practices, please read our Privacy Policy.
 
Add
Remove
Back
Back

Stay in Touch

Have questions? We're here to help.

 Contact Us
Copyright © 2004- Genomic Health, Inc. All Rights Reserved.
In the US and certain other jurisdictions, Genomic Health, Oncotype, Oncotype DX, Oncotype IQ, Oncotype MAP, Breast Recurrence Score, Recurrence Score, DCIS Score, Colon Recurrence Score, Genomic Prostate Score, GPS, AR-V7 Nucleus Detect, Pass It On: Until Every Woman Knows, and Making Cancer Care Smarter are trademarks of Genomic Health, Inc. Exact Sciences is a trademark of Exact Sciences Corporation.
Making cancer care smarter.™